Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Reverse transcriptase drug resistance mutations in HIV-1 subtype C infected patients on ART in Karonga District, Malawi.

Bansode VB, Travers SA, Crampin AC, Ngwira B, French N, Glynn JR, McCormack GP.

AIDS Res Ther. 2011 Oct 13;8(1):38. doi: 10.1186/1742-6405-8-38.

2.

Drug resistance mutations in drug-naive HIV type 1 subtype C-infected individuals from rural Malawi.

Bansode V, Drebert ZJ, Travers SA, Banda E, Molesworth A, Crampin A, Ngwira B, French N, Glynn JR, McCormack GP.

AIDS Res Hum Retroviruses. 2011 Apr;27(4):439-44. doi: 10.1089/aid.2010.0203. Epub 2010 Oct 15.

3.

Limited evolution but increasing trends of primary non-nucleoside reverse transcriptase inhibitor resistance mutations in therapy-naive HIV-1-infected individuals in India.

Neogi U, Gupta S, Palchaudhuri R, Rao SD, Shastri S, Diwan V, Laishram RS, De Costa A, Shet A.

Antivir Ther. 2014;19(8):813-8. doi: 10.3851/IMP2769. Epub 2014 Apr 4.

PMID:
24699043
4.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
5.

Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco.

El Annaz H, Recordon-Pinson P, Tagajdid R, Doblali T, Belefquih B, Oumakhir S, Sedrati O, Mrani S, Fleury H.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):944-8. doi: 10.1089/AID.2011.0278. Epub 2011 Nov 23.

6.

Prevalence of HIV drug resistance mutation in the northern Indian population after failure of the first line antiretroviral therapy.

Sinha S, Shekhar RC, Ahmad H, Kumar N, Samantaray JC, Sreenivas V, Khan NH, Mitsuyasu RT.

Curr HIV Res. 2012 Sep;10(6):532-8.

PMID:
22716105
7.

Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India.

Karade SK, Ghate MV, Chaturbhuj DN, Kadam DB, Shankar S, Gaikwad N, Gurav S, Joshi R, Sane SS, Kulkarni SS, Kurle SN, Paranjape RS, Rewari BB, Gangakhedkar RR.

Medicine (Baltimore). 2016 Sep;95(37):e4886. doi: 10.1097/MD.0000000000004886.

8.

Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.

Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, Butel C, Montavon C, Mpoudi-Ngole E, Delaporte E, Peeters M.

AIDS. 2011 Nov 13;25(17):2183-8. doi: 10.1097/QAD.0b013e32834bbbe9.

PMID:
21860346
9.

HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design.

Nanfack AJ, Takou D, Fokam J, Salpini R, Santoro MM, Cappelli G, Baane M, Tetang SM, Eberle J, Gürtler L, Ceccherini-Silberstein F, Torimiro JN, Colizzi V, Perno CF, Ndjolo A.

Curr HIV Res. 2016 Dec 29. [Epub ahead of print]

PMID:
28034359
10.

High Rates of Drug Resistance Among Newly Diagnosed HIV-infected Children in the National Prevention of Mother-to-child Transmission Program in Togo.

Salou M, Butel C, Konou AA, Ekouevi DK, Vidal N, Dossim S, Lawson-Evi K, Nyasenu YT, Singo-Tokofaï A, d'Almeida S, Tchama R, Delaporte E, Prince-David M, Peeters M, Dagnra AY.

Pediatr Infect Dis J. 2016 Aug;35(8):879-85. doi: 10.1097/INF.0000000000001203.

PMID:
27167115
11.

Distinctive Drug-resistant Mutation Profiles and Interpretations of HIV-1 Proviral DNA Revealed by Deep Sequencing in Reverse Transcriptase.

Yin QQ, Li ZP, Zhao H, Pan D, Wang Y, Xu WS, Xing H, Feng Y, Jiang SB, Shao YM, Ma LY.

Biomed Environ Sci. 2016 Apr;29(4):239-47. doi: 10.3967/bes2016.031.

12.

Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.

Winters MA, Lloyd RM Jr, Shafer RW, Kozal MJ, Miller MD, Holodniy M.

PLoS One. 2012;7(7):e40514. doi: 10.1371/journal.pone.0040514. Epub 2012 Jul 18.

13.

In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa.

Villabona-Arenas CJ, Vidal N, Guichet E, Serrano L, Delaporte E, Gascuel O, Peeters M.

AIDS. 2016 Nov 13;30(17):2577-2589.

PMID:
27603287
14.

Exposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaques.

Hsu M, Keele BF, Aravantinou M, Krawczyk N, Seidor S, Abraham CJ, Zhang S, Rodriguez A, Kizima L, Derby N, Jean-Pierre N, Mizenina O, Gettie A, Grasperge B, Blanchard J, Piatak MJ Jr, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M.

PLoS One. 2014 Feb 27;9(2):e89300. doi: 10.1371/journal.pone.0089300. eCollection 2014.

15.

Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.

Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Stevens WS, Rinke de Wit TF, Schuurman R; PharmAccess African Studies to Evaluate Resistance (PASER)..

Clin Infect Dis. 2012 Jun;54(11):1660-9. doi: 10.1093/cid/cis254. Epub 2012 Apr 3.

PMID:
22474222
16.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, De Oliveira T, Wensing AM, Gallant JE, Wainberg MA, Richman DD, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, Shafer RW.

PLoS One. 2015 Dec 30;10(12):e0145772. doi: 10.1371/journal.pone.0145772. eCollection 2015.

17.

Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries.

Ekici H, Rao SD, Sönnerborg A, Ramprasad VL, Gupta R, Neogi U.

J Antimicrob Chemother. 2014 Dec;69(12):3349-55. doi: 10.1093/jac/dku278. Epub 2014 Jul 31.

PMID:
25085657
18.

HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA.

de Mulder M, York VA, Wiznia AA, Michaud HA, Nixon DF, Holguin A, Rosenberg MG.

HIV Med. 2014 Mar;15(3):135-43. doi: 10.1111/hiv.12089. Epub 2013 Sep 25.

19.

Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.

Palombi L, Galluzzo CM, Andreotti M, Liotta G, Jere H, Sagno JB, Luhanga R, Mancinelli S, Amici R, Marazzi MC, Vella S, Giuliano M.

J Antimicrob Chemother. 2015 Oct;70(10):2881-4. doi: 10.1093/jac/dkv171. Epub 2015 Jun 25.

PMID:
26111981
20.

Prevalence of HIV-1 Subtypes and Antiretroviral Drug Resistance Mutations in Nepal.

Bhusal N, Sutthent R, Horthongkham N, Athipanyasilp N, Kantakamalakul W.

Curr HIV Res. 2016;14(6):517-524.

PMID:
27697032

Supplemental Content

Support Center